Diamyd Medical AB
Additional Pharma Competence proposed for Diamyd Board of Directors
Diamyd Medical AB / 26.11.2009 Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- The shareholders of Diamyd Medical AB (publ) are summoned to the Annual General Meeting on Friday December 11, 2009 at 3:00 p.m. at the IVA Conference Center, Grev Turegatan 16 (Wallenberg auditorium) in Stockholm. Under item 11 in the agenda, Diamyd's Nomination Committee now proposes that an additional Director is elected to the Board of Directors. The Nomination Committee proposes that Göran Pettersson is elected to Diamyd's Board of Directors. Göran Pettersson, with degrees in Pharmacy and Marketing, has a long background from leading business functions in the Astra group, KabiVitrum AB, KabiPharmacia/Pharmacia&Upjohn AB and Meda AB. He is currently a Director of the Boards of Medivir AB, OxyPharma AB, Recipharm AB, Swedish Orphan AB and Vivoxid, Oy. 'We welcome Göran as candidate to Diamyd's Board of Directors. He adds extensive business experience from the pharmaceutical industry and complements the current board in an excellent way,' says Elisabeth Lindner, CEO and President of Diamyd Medical. In accordance with the published agenda, resolutions for items 9-11 are proposed as follows (changes are underlined): Election of Board Members and remuneration etc., items 9-11 The Nomination Committee proposes the re-election of current directors Anders Essen-Möller, Lars Jonsson, Sam Lindgren and Henrik Bonde, and the election of Maria-Teresa Essen-Möller and Göran Petterson. The Committee proposes the re-election of Anders Essen-Möller as Chairman of the Board. The proposed Board Members' remuneration is SEK 100,000 for each of the Board Members who are not employed at the Company, totaling SEK 500,000. (The Chairman of the Board is a Company employee.) Remuneration includes work on Board committees. It is proposed that the auditors should receive remuneration according to an approved account. For more information, please contact: Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.) Phone: +46 8 661 0026 For pictures and press material, please contact: Andreas Ericsson, Diamyd Medical AB (publ.) andreas.ericsson@diamyd.com Phone: +46 8 661 0026 About Diamyd Medical Diamyd Medical is a Swedish diabetes company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications. The company's most advanced project is the GAD-based drug Diamyd(R) for type 1 diabetes. Phase III trials for this drug are in progress in both Europe and the US. In addition, the company has initiated clinical studies in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson's disease. The company currently has three clinical-phase products. Diamyd Medical has offices in Sweden and in the US. Shares are listed on Nasdaq OMX in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is available on the company's website: www.diamyd.com. This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements. Diamyd Medical AB (publ.) Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Tel: +46 (0)8 6610026, Fax: +46 (0)8 661 63 68 E-mail: info@diamyd.com. VAT no: SE556530-142001. News Source: NASDAQ OMX 26.11.2009 Financial News distributed by DGAP. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Diamyd Medical AB Sweden Phone: Fax: E-mail: Internet: ISIN: SE0000337917 WKN: End of News DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden